Craft
  • Home
  •  / Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical

Revenue

¥120.2 B

FY, 2022

Hisamitsu Pharmaceutical Summary

Company summary

Overview
Hisamitsu Pharmaceutical (久光製藥株式會社) is a company manufacturing external analgesic and anti-inflammatory preparations, such as medicated plasters, gels, sprays, etc. It develops transdermal anti-inflammatory analgesic drugs, including patches SALONPAS designed to treat pain and stiffness.
Type
Public
Status
Active
Founded
1847
HQ
Tosu, JP | view all locations
Website
https://global.hisamitsu/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • NAKATOMI Kazuhide

    NAKATOMI Kazuhide, President & CEO

    • Jim Lepis

      Jim Lepis, Director of Marketing for Hisamitsu America

    • John Incledon

      John Incledon, President and CEO at Hisamitsu America

    LocationsView all

    26 locations detected

    • Tosu, Saga HQ

      Japan

      408 Tashiro Daikancho

    • Florham Park, NJ

      United States

      100 Campus Dr #117

    • Manaus, AM

      Brazil

      Av. Buriti, 1050 Distrito Industrial

    • Beijing, Beijing Shi

      China

      East Ocean Centre, Room 504, 24 Jian Guo Men Wai Avenue

    • Suzhou, Jiangsu

      China

      Rm♯, 1805, 18F, No.1 Unit, Suzhou International Wealth Square, No.9 West Suzhou Avenue

    • Hong Kong, Kowloon

      Hong Kong

      OfficeE, 9th Floor, MG Tower, No.133 Hoi Bun Road

    and 20 others

    Hisamitsu Pharmaceutical Financials

    Summary financials

    Revenue (Q2, 2023)
    ¥33.2B
    Gross profit (Q2, 2023)
    ¥20.8B
    Net income (Q2, 2023)
    ¥5.0B
    Cash (Q2, 2023)
    ¥136.5B
    EBIT (Q2, 2023)
    ¥4.4B

    Footer menu